Table of Contents

1. Summary **1**

2. Zusammenfassung **3**

3. Introduction **5**

3.1. The selectivity of anticancer drugs 5

3.2. Antibodies 6

3.2.1. Antibody structure and function 6

Antibody-dependent cellular cytotoxicity (ADCC) *8*

Complement-dependent cytotoxicity (CDC) *9*

3.2.2. Engineering antibodies for cancer therapy 11

Engineering the Fc domain of IgGs to modulate effector functions *12*

Antibody formats and their targeting properties *13*

3.2.3. Therapeutic antibodies and their mechanisms of action 16

3.2.4. Antibody targets 18

Vascular tumor targeting *20*

3.3. Armed antibodies 23

3.3.1. Immunocytokines 24

Cytokine moieties of immunocytokines *27*

IL2-based immunocytokines *29*

3.3.2 Antibody-Drug Conjugates 31

ADC targets, formats and function *32*

Conjugation strategies and ADC linker technologies *34*

Cytotoxic payloads *38*

Clinical stage ADCs *41*

3.4. Acute Myeloid Leukemia 50

3.4.1. Disease and classification 51

3.4.2 Treatment of AML 53

Antibody-based therapies *54*

3.5 Aim of thesis 56

4. Results **58**

4.1. Immunochemical analysis of the expression of vascular targeting antigens in AML patient specimens 59

4.2. Generation of mouse models of leukemia: analysis of antigen expression and targeting by biodistribution studies 64

4.2.1 systemic AML models 64

Gutbrodt, Katrin Lisa
Armed vascular targeting antibodies for the treatment of ...
2014

digitalisiert durch
IDS Basel/Bern, im Auftrag der
Schweizerischen Nationalbibliothek

4.3. F8-IL2 immunocytokine in combination with cytarabine 68
4.3.1 Therapeutic effect of F8-IL2 and cytarabine in NB4 xenograft model 68
4.3.2 Therapeutic effect of F8-IL2 and cytarabine in syngeneic C1498 model 70
4.3.3. Clinical evaluation of F16-IL2 in combination with low-dose cytarabine 73
4.4 Combination of immunocytokines and ADCs 75
4.4.1 Generation and characterization of armed antibody products 76
4.4.2 Therapeutic effect of F8-IL2 in combination with F8-SS-CH_2Cem 78

5. Discussion 81

5.1. Vascular targeting IL2-immunocytokines in combination with cytarabine for the treatment of AML 81
5.2. Combining IL2-based immunocytokines with ADCs 86

6. Conclusions and outlook 89

7. Materials and methods 94

7.1 Immunochemical analysis of leukemia specimens 94
7.1.1 Study design and tissues 94
7.1.2 Antibodies 95
7.1.3 Immunofluorescence 95
Semi-quantitative analysis of immunofluorescence 96
7.1.4 Immunohistochemistry 96
7.2 Mouse models of AML 97
7.2.1 Cell lines and animals 97
7.2.2 Immunofluorescence of murine tumor and bone marrow specimens 97
7.2.3 Orthotopic xenograft model 98
Verification of disease progression in HL60 model 98
7.2.4 Localized xenograft (chloroma) model 99
Quantitative biodistribution studies 99
7.3 F8-IL2 in combination with cytarabine 100
7.3.1 Therapeutic agents 100
7.3.2 Therapy studies in localized xenograft (chloroma) models 100
7.3.3 *In vivo* depletion of NK cells, $CD4^+$ and $CD8^+$ T cells 101
7.3.4 Treatment of a chloroma patient 101
7.4 F8-IL2 in combination with ADCs 104
7.4.1 Cell lines, animals, and xenograft models 104
7.4.2 Antibodies 104
7.4.3 Preparation of ADCs 104

7.4.4 Characterization of the armed antibody products 104
7.4.5 Combination therapy and tumor re-challenge in the localized C1498 model 105
7.4.6 *In vivo* depletion of NK cells, $CD4^+$ T cells, and $CD8^+$ T cells 106

8. Copyright 107

9. List of abbreviations 108

10. References 110

11. Appendix 124

11.1 Complete panel of stainings for immunochemical analysis of the expression of vascular targeting antigens in AML and ALL patient specimens 124
11.2 Characterization of the analyzed AML and ALL patients 128
11.3 Cytarabine dose finding in subcutaneous NB4 mouse model 130
11.4 Generation of traceless site-selective disulfide linked ADCs in the SIP format 131
11.5 Expression of an anti-hCD33 antibody in SIP format and analysis of AML targeting properties. 132
11.6 Sequence of anti–hCD33 antibody in SIP format 134

12. Acknowledgments 136

13. Curriculum Vitae 138